翻訳と辞書 |
Rinat Neuroscience Corporation : ウィキペディア英語版 | Rinat Neuroscience Corporation Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs including: * Tanezumab (codenamed RN624)., a monoclonal antibody against nerve growth factor for the treatment of pain * Ponezumab (codenamed RN1219),〔(【引用サイトリンク】url=http://www.alzforum.org/therapeutics/ponezumab )〕 a monoclonal antibody against Beta amyloid for the treatment of Alzheimer's disease * LBR-101 (codenamed RN307),〔(【引用サイトリンク】url=http://www.nasdaq.com/press-release/teva-completes-acquisition-of-labrys-opens-door-to-a-strong-and-novel-migraine-prevention-and-20140721-00295 )〕 a monoclonal antibody against Calcitonin gene-related peptide for the treatment of migraines * Bococizumab (codenamed RN316), a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol Rinat was founded in 2001 by Arnon Rosenthal〔(【引用サイトリンク】url=http://investing.businessweek.com/research/stocks/private/person.asp?personId=27851460&privcapId=1288518 )〕 and Patrick Lynn,〔(【引用サイトリンク】url=http://investing.businessweek.com/research/stocks/private/person.asp?personId=77688&privcapId=36882503 )〕 following a broad licensing agreement with Genentech,〔(【引用サイトリンク】url=http://www.gene.com/media/press-releases/7907/2004-11-09/genentech-and-rinat-neuroscience-announc )〕 and was acquired by Pfizer in 2006 for approximately $500M.〔(【引用サイトリンク】url=http://www.pfizer.be/sites/be/nl/media/press_bulletins/research_and_development_and_business_development/Pages/Pfizertoexpandneuroscienceresearchwithacquisitionofbiotechcompanyrinatneuroscience.aspx )〕 Rinat currently operates as an independent biotechnology unit within Pfizer's Worldwide R&D group in South San Francisco〔(【引用サイトリンク】url=http://www.pfizer.com/partnering/areas_of_interest/rinat )〕 ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Rinat Neuroscience Corporation」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|